Interní Med. 2001; 3(1): 8-12

Léčba fibrilace a flutteru síní

prof. MUDr. Jan Lukl CSc
I. interní klinika FN a LF UP Olomouc

Keywords: fibrilace síní, flutter síní, digoxin, antiarytmika, trombembolie, antikoagulace, radiofrekvenení katetrová ablace.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukl J. Léčba fibrilace a flutteru síní. Interní Med. 2001;3(1):8-12.

V přehledu upozorňujeme na zásady farmakologické i nefarmakologické léčby fibrilace a flutteru síní včetně odlišností v postupu u obou arytmií. Podle závažnosti symptomů, potenciálních komplikací a trvání arytmie se rozhodujeme buď pro verzi arytmie na sinusový rytmus s následnou prevencí recidiv nebo pro kontrolu srdeční frekvence. U recidivující i chronické fibrilace nebo flutteru síní je zvláště při existenci rizikových faktorů nutné provádět prevenci trombembolických komplikací trvalou antikoagulací.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boysen G., Nyobe J., Appleyard M.: Stroke incidince and risk factors for stroke in Copenhagen. Denmark. Stroke. 1988, 19, s 1345-1353. Go to original source... Go to PubMed...
    2. Schreck D.M., Rivera A. R., Tricarico V. J.: Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997, 29, s. 135-140. Go to original source... Go to PubMed...
    3. Beasley R., Smith D.A., McHaffie D.J.: Exercise heart rate at different serum digoxin concentration in patients with atrial fibrillation Brit Med J 1985, 290, s. 9-11. Go to original source... Go to PubMed...
    4. Coplen S.E., Antman E.M., Berlin J.A., et al.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized controlled trials. Circulation 1990, 82, s. 1106-1116. Go to original source... Go to PubMed...
    5. Boriani G., Biffi M., Cappucci A., et al.: Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. PACE 1998, 21, s. 2470-2474. Go to original source... Go to PubMed...
    6. Niebauer M.J., Bash D., Chung M.K., et al.: Cardioversion thresholds of atrial fibrillation and atrial flutter using an external biphasic waveform defibrillator. PACE 2000, 23, s. 605 (abstract).
    7. Roy D. Talajic M., Dorian P., et al.: Amiodarone to prevent recurrence of atrial fibrillation. A Engl J Med 2000, 342, s. 913-920. Go to original source... Go to PubMed...
    8. Gerstenfeld E.P., Groenewegen A.S., Lux R.I., et al.: An optimal set for localizing atrial activation originating from the pulmonary veins. PACE 2000, 23, s. 583 (abstract).
    9. Fiala M., Heinc P., Lukl J.: Katetrové ablace flutteru síní I. typu u pacientů se složitým arytmogenním substrátem. Sborník abstrakt z V. Českého sympozia o arytmiích a kardiostimulaci, Olomouc, 1998.
    10. Falk R. H.: Antithrombotic therapy in atrial fibrillation. in: Falk R.H., Podrid P.J.(Ed): Atrial fibrillation - mechanisms and management. Lippincott - Raven, Philadelphia, N.Y. 1997, s. 277.
    11. Manning W.J., Silverman D.I., Keighley C.S., et al.: Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5 year study. J Am Coll Cardiol 1995, 25, s. 1354-1361. Go to original source... Go to PubMed...
    12. Gillighan D.M., Fuller I.A., Prinz A., et al.: The importance of distinguishing typical from atypical atrial flutter in assessing the risk of left atrial thrombus. J Am Coll Cardiol 2000, 101,102A (abstract).

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.